The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2022-11-01 DOI:10.1097/WNF.0000000000000519

Aleksandra Topic, Marija Vasic, Bojan Markovic, Neda Milinkovic, Evica Dincic

{"title":"The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis.","authors":"Aleksandra Topic, Marija Vasic, Bojan Markovic, Neda Milinkovic, Evica Dincic","doi":"10.1097/WNF.0000000000000519","DOIUrl":null,"url":null,"abstract":"Objective: Oxidative stress (OS) has a role in the pathogenesis and progression of multiple sclerosis. The effects of disease-modifying therapies (DMTs) on OS are unclear. We aimed to explore the association between DMTs and OS in patients with relapsing-remitting multiple sclerosis (RRMS).Methods: The study conducted in 167 patients (102 received and 65 not received the DMTs). The DMTs included interferon beta-1a (n = 15), interferon beta-1b (n = 20), glatiramer acetate (n = 10), and sphingosine-1-phosphate receptor modulators (n = 57). Oxidative stress assessed by total antioxidant status (TAS) and total oxidant status (TOS) (determined by spectrophotometric method), oxidative index (OSI was calculated), and urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG/creatinine was determined by high-performance liquid chromatography and tandem mass spectrometry). Patients were classified by Multiple Sclerosis Severity Score (MSSS) to mild/moderate (MSSS, <6.7) and severe (MSSS, >6.7).Results: Disease-modifying therapies are associated with increased TAS, decreased TOS, OSI, and 8-oxodG/creatinine. Regardless of therapy, women had a less favorable redox status (lower TAS, higher TOS and OSI). Patients with MSSS>6.7 and without DMTs had higher OSI than patients who received DMTs. Women with MSSS>6.7 without DMTs had lower TAS than women with DMTs, whereas in the same stage of MS, men without DMTs had higher TOS than patients with DMTs. Women with MSSS<6.7 and with DMTs had lower 8-oxodG/creatinine compared with those without DMT therapy.Conclusions: The antioxidant effects of DMTs were evidenced in this study. The gender-related effects of DMTs on the OS imply the personalized antioxidant pharmacotherapy, especially for the women. The OS biomarkers have a potential as the prognostic for the assessment of DMTs outcomes in patients with RRMS.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"45 6","pages":"157-161"},"PeriodicalIF":0.8000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000519","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Oxidative stress (OS) has a role in the pathogenesis and progression of multiple sclerosis. The effects of disease-modifying therapies (DMTs) on OS are unclear. We aimed to explore the association between DMTs and OS in patients with relapsing-remitting multiple sclerosis (RRMS).

Methods: The study conducted in 167 patients (102 received and 65 not received the DMTs). The DMTs included interferon beta-1a (n = 15), interferon beta-1b (n = 20), glatiramer acetate (n = 10), and sphingosine-1-phosphate receptor modulators (n = 57). Oxidative stress assessed by total antioxidant status (TAS) and total oxidant status (TOS) (determined by spectrophotometric method), oxidative index (OSI was calculated), and urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG/creatinine was determined by high-performance liquid chromatography and tandem mass spectrometry). Patients were classified by Multiple Sclerosis Severity Score (MSSS) to mild/moderate (MSSS, <6.7) and severe (MSSS, >6.7).

Results: Disease-modifying therapies are associated with increased TAS, decreased TOS, OSI, and 8-oxodG/creatinine. Regardless of therapy, women had a less favorable redox status (lower TAS, higher TOS and OSI). Patients with MSSS>6.7 and without DMTs had higher OSI than patients who received DMTs. Women with MSSS>6.7 without DMTs had lower TAS than women with DMTs, whereas in the same stage of MS, men without DMTs had higher TOS than patients with DMTs. Women with MSSS<6.7 and with DMTs had lower 8-oxodG/creatinine compared with those without DMT therapy.

Conclusions: The antioxidant effects of DMTs were evidenced in this study. The gender-related effects of DMTs on the OS imply the personalized antioxidant pharmacotherapy, especially for the women. The OS biomarkers have a potential as the prognostic for the assessment of DMTs outcomes in patients with RRMS.

查看原文本刊更多论文

疾病修饰疗法对复发缓解型多发性硬化症患者氧化应激的影响

目的:氧化应激(Oxidative stress, OS)在多发性硬化症(multiple sclerosis，简称ms)的发病和发展过程中起重要作用。疾病修饰疗法(dmt)对OS的影响尚不清楚。我们旨在探讨复发-缓解型多发性硬化症(RRMS)患者的dmt和OS之间的关系。方法:167例患者(102例接受dmt治疗，65例未接受dmt治疗)。DMTs包括干扰素β -1a (n = 15)、干扰素β -1b (n = 20)、醋酸格拉替胺(n = 10)和鞘氨醇-1-磷酸受体调节剂(n = 57)。氧化应激通过总抗氧化状态(TAS)和总氧化状态(TOS)(分光光度法测定)、氧化指数(OSI计算)和尿8-氧-7,8-二氢-2'-脱氧鸟苷(8-氧/肌酐采用高效液相色谱和串联质谱法测定)来评估。根据多发性硬化严重程度评分(MSSS)将患者分为轻度/中度(MSSS, 6.7)。结果:疾病改善治疗与TAS升高、TOS降低、OSI和8-oxodG/肌酐相关。无论采用何种治疗方法，女性的氧化还原状态较差(TAS较低，TOS和OSI较高)。MSSS>6.7且未接受dmt治疗的患者的OSI高于接受dmt治疗的患者。MSSS>6.7且无DMTs的女性TAS低于有DMTs的女性，而在同一MS阶段，无DMTs的男性TOS高于有DMTs的患者。结论:本研究证实了DMTs的抗氧化作用。dmt对OS的性别相关影响意味着个体化抗氧化药物治疗，特别是对女性。OS生物标志物有潜力作为评估RRMS患者dmt预后的预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.